Indaptus Therapeutics, Inc. Operating Lease Liability
Indaptus Therapeutics, Inc. (INDP) had Operating Lease Liability of $8.69 thousand as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2025-11-12
- 2025-09-30: Operating Lease, Liability $8.69K.
- 2025-06-30: Operating Lease, Liability $34.37K.
- 2025-03-31: Operating Lease, Liability $59.51K.
- 2024-12-31: Operating Lease, Liability $84.16K.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-09-30 | $8.69K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $34.37K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $59.51K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $84.16K 10-K · filed 2025-03-13 |
| 2024-09-30 | $107.99K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $130.80K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $153.13K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $175.05K 10-K · filed 2024-03-13 |
| 2023-09-30 | $196.24K 10-Q · filed 2023-11-06 |
| 2023-06-30 | $216.59K 10-Q · filed 2023-08-14 |
| 2023-04-19 | $236.51K 10-K · filed 2025-03-13 |
| 2023-03-31 | $236.51K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $80.49K 10-K · filed 2023-03-17 |
| 2022-09-30 | $103.57K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $125.81K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $147.70K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $169.33K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |